FIELD: pharmaceutics.
SUBSTANCE: invention relates to compounds of formula (I)
where R1 is C1-6alkyl, where R1 can be substituted with one R5; k equals 0; R3 is halogen; n is 0–2; R4 is halogen; m is 0–2; A is =N- or =C(R6)-; R5 is hydroxy; R6 is hydrogen; or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition and a method of treating diseases or disorders mediated in whole or in part by BTK, and a method of inhibiting BTK.
EFFECT: novel compounds are obtained, which have inhibitory activity on BTK, where BTK is a wild-type BTK or BTK with a C481 mutation.
17 cl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMIDAZOTRIAZINONE COMPOUNDS | 2011 |
|
RU2603140C2 |
| mTOR KINASE INHIBITORS FOR ONCOLOGICAL INDICATIONS AND DISEASES METABOLICALLY BOUND TO mTOR/PI3K/AKT | 2009 |
|
RU2546658C2 |
| NEW IMIDAZO[4,5-c]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | 2018 |
|
RU2773516C2 |
| BICYCLIC PIPERAZINE COMPOUNDS | 2012 |
|
RU2628616C2 |
| HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
| PYRROLOTRIAZINE DERIVATIVES AS KINASE INHIBITOR | 2018 |
|
RU2726632C1 |
| MTOR KINASE INHIBITORS FOR ONCOLOGIC INDICATIONS AND DISEASES ASSOCIATED WITH MTOR/PI3K/AKT BY METABOLISM | 2009 |
|
RU2692796C2 |
| NEW DERIVATIVES OF IMIDAZO [4,5-C] QUINOLINES AND IMIDAZO [4,5-C] [1,5] NAPHTHYRIDINES AS LRRK2 INHIBITORS | 2016 |
|
RU2722149C1 |
| COMPOUNDING, WHICH INHIBITES ACTIVITY OF BTK AND/OR JAK3 KINASES | 2014 |
|
RU2650512C2 |
| METHODS OF OBTAINING AND PURIFICATION OF HETEROARYL COMPOUNDS | 2010 |
|
RU2557242C2 |
